Agoracom: Small Cap Investment - Zenith Epigenetics - Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

BearDownAZ

Jun 13, 2016 04:27PM

Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

Jkj193741

Jun 13, 2016 09:25PM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

in response to

Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.

Jkj193741

posted on Jun 14, 2016 07:25AM

Yes, this is the same RVX-297. However, since Zenith has removed pretty much any mention of an autoimmune program from their website when they re-designed the site for prostate cancer/oncology focus, I am not sure if Zenith is still pursuing RVX-297 and other similar compounds for autoimmune indications.